Enforcement Report - Week of April 12, 2023
Enforcement Report - Week of May 18, 2022
Enforcement Report - Week of May 11, 2022
Enforcement Report - Week of March 23, 2022
Enforcement Report - Week of March 16, 2022
Enforcement Report - Week of February 23, 2022
In its first public safety alert in six years, the Drug Enforcement Administration is warning about a dramatic increase in fake prescription drugs being sold on the black market containing a potentially lethal dose of fentanyl.
The U.S. Food and Drug Administration announced today in a Drug Safety Communication that it is requiring an update to the Boxed Warning, the agency’s most prominent safety warning, and requiring class-wide labeling changes for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions to help improve their safe use.
Belgian biopharmaceutical firm UCB has acquired US-based pharmaceutical company Engage Therapeutics for a cash consideration of $125m.
UCB announced today the acquisition of Engage Therapeutics, Inc. (Summit, N.J. (U.S.)), a clinical-stage pharmaceutical company developing Staccato® Alprazolam for the rapid termination of an active epileptic seizure, for US$ 125 million in cash (subject to certain adjustments) and up to US$ 145 million in further potential milestone payments related to clinical development, submission and launch of Staccato® Alprazolam.